Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) ClinicalTrials.gov Identifier : NCT03202303 Recruitment Status : Not yet recruiting First Posted : June 28, 2017 Last Update Posted : April 2, 2019 https://clinicaltrials.gov/ct2/show/NCT03202303?term=cannabinoids&cond=Autism+Spectrum+Disorder&rank=2 Sponsor : Eric Hollander Collaborators : United States Department of Defense, GW Pharmaceuticals Information provided by (Responsible Party) : Eric Hollander, Montefiore Medical Center, USA Study Design Study Type : Interventional (Clinical Trial) Estimated Enrollment : 100 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Phase 2, 12-week double-blind, randomized, placebo-controlled trial Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Masking Description: Double-Blind Primary Purpose: Treatment Official Title: Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) Estimated Study Start Date : June 2019 Estimated [...]
Lire la suiteIncreased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression LYONS T., CARHART-HARRIS R.L. Journal of Psychopharmacology, 2018, 32, 7, 811-819. Doi : 10.1177/0269881117748902 journals.sagepub.com/home/jop Abstract Rationale : Previous research suggests that classical psychedelic compounds can induce lasting changes in personality traits, attitudes and beliefs in both healthy subjects and patient populations. Aim : Here we sought to investigate the effects of psilocybin on nature relatedness and libertarian authoritarian political perspective in patients with treatment-resistant depression (TRD). Methods : This open-label pilot study with a mixed-model design studied the effects of psilocybin on measures of nature relatedness and libertarian– authoritarian political perspective in patients with [...]
Lire la suite